These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28935493)

  • 61. Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.
    Kubo N; Harada T; Shiraishi Y; Nosaki K; Nakagaki N; Takeshita M; Ouchi H; Iwama E; Tanaka K; Okamoto I; Sasaki H; Nakanishi Y
    Anticancer Res; 2019 Feb; 39(2):671-677. PubMed ID: 30711944
    [TBL] [Abstract][Full Text] [Related]  

  • 62. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 64. There is still a role for cytology in the 'liquid biopsy' era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression.
    Clery E; Pisapia P; Feliciano S; Vigliar E; Marano A; De Luca C; Malapelle U; Troncone G; Bellevicine C
    J Clin Pathol; 2017 Sep; 70(9):798-802. PubMed ID: 28363898
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumor-educated platelet as liquid biopsy in lung cancer patients.
    Liu L; Lin F; Ma X; Chen Z; Yu J
    Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
    Johnson AC; Dô P; Richard N; Dubos C; Michels JJ; Bonneau J; Gervais R
    Lung Cancer; 2016 Sep; 99():38-40. PubMed ID: 27565911
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
    Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
    Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer.
    Dai LJ; Wang C; Ding ZY
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1761-1766. PubMed ID: 30049184
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.
    Mairinger FD; Vollbrecht C; Streubel A; Roth A; Landt O; Walter HF; Kollmeier J; Mairinger T
    Appl Immunohistochem Mol Morphol; 2014; 22(2):114-8. PubMed ID: 24517913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer.
    Hsiao SH; Chung CL; Lee CM; Chen WY; Chou YT; Wu ZH; Chen YC; Lin SE
    Clin Lung Cancer; 2013 Nov; 14(6):719-25. PubMed ID: 23891241
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
    Melosky B; Popat S; Gandara DR
    Clin Lung Cancer; 2018 Jan; 19(1):42-50. PubMed ID: 28668205
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer.
    Claus J; De Smet D; Breyne J; Wesolowski J; Himpe U; Demedts I; Martens GA
    Sci Rep; 2024 Aug; 14(1):18191. PubMed ID: 39107402
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 76. EGFR Mutation Analysis in Non-small Cell Lung Carcinoma from Tissue Samples Using the Fully Automated Idylla™ qPCR System.
    Heeke S; Hofman P
    Methods Mol Biol; 2019; 2054():147-155. PubMed ID: 31482454
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma.
    Yang CY; Hsieh MS; Liao WY; Shih JY; Yu CJ
    J Oncol Pract; 2019 Feb; 15(2):115-118. PubMed ID: 30763203
    [No Abstract]   [Full Text] [Related]  

  • 78. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
    Riely GL
    J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Diagnostic Accuracy of Liquid Biopsy in EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis of 40 Studies.
    Wang N; Zhang X; Wang F; Zhang M; Sun B; Yin W; Deng S; Wan Y; Lu W
    SLAS Technol; 2021 Feb; 26(1):42-54. PubMed ID: 32659150
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Immunohistochemical detections of EGFR mutations in NSCLC].
    Liu C; Xu D; Zhong D
    Zhongguo Fei Ai Za Zhi; 2014 Sep; 17(9):701-5. PubMed ID: 25248714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.